Type 2 Diabetes Path to Remission Programme- Guidance or GP Practices and Referrers(462 KB) - Guidelines
Version 1
Uploaded September 2023
Date added: 21st Sep 2023
| Drug Name | Classification | Clinical Indication | Comments |
|---|---|---|---|
| APOMORPHINE | Orange | Parkinson's disease | |
| BUDESONIDE/ FORMOTEROL FUMARATE DIHYDRATE INHALER (GoResp Digihaler®) (NEW) | Grey | Asthma & COPD |
Not yet reviewed |
| BUSPIRONE | Yellow | Anxiety |
Specialist psychiatrist initiation only. |
| DAPAGLIFLOZIN (Forxiga®) (UPDATED) | Yellow | Chronic Heart failure with reduced ejection fraction and preserved ejection fraction |
In line with NICE TA679 and NICE TA902 |
| Dexcom ONE® Glucose Monitoring System (NEW) | Yellow | Diabetes glucose monitoring for those included on the LLRAPC position statement |
Eligibility as per LLRAPC documents. Initial six months trial. Please see relevant documents for initiation and continuation. |
| ENOXAPARIN (Inhixa®) | Yellow | VTE prophylaxis for antenatal indications | |
| FAVIPIRAVIR (Avigan®) (NEW) | Red | For treatment of Chronic Norovirus related to immunodeficiency | |
| FERROUS FUMARATE | Green | Iron Deficiency Anaemia |
Recommended ONCE DAILY dosage in adults as per NICE CKS and British Society of Gastroenterology |
| FERROUS SULPHATE | Green | Iron Deficiency Anaemia |
Recommended ONCE DAILY dosage in adults as per NICE CKS and British Society of Gastroenterology |
| FreeStyle Libre 2® Sensor (UPDATED) | Yellow | Diabetes glucose monitoring for those included on the LLRAPC position statement. |
Eligibility as per LLRAPC documents. Initial six month trial. Please see relevant documents for initiation and continuation.
|
| LIOTHYRONINE | Red | Treatment of depression where other therapies have failed |
This should be under the advice of an NHS consultant psychiatrist. In line with NICE NG222 |
| PROGESTERONE (Gepretix®) (NEW) | Grey | For adjunctive use with an oestrogen in post-menopausal women with an intact uterus, as hormone replacement therapy (HRT). |
Not yet reviewed. |
| RIMEGEPANT (Vydura®) | Grey | Acute treatment of migraine with or without aura in adults |
Not yet reviewed. |
| RIMEGEPANT (Vydura®) (NEW) | Red | For preventing migraine |
In line with NICE TA906 |
| Semaglutide (Wegovy®) (UPDATED) | Do not prescribe | Weight management in overweight and obese adults |
Work is ongoing locally to plan for the implementation of NICE TA875. Semaglutide will only be available to patients that meet the eligibility criteria outlined by NICE and only through a specialist weight management service. |
| TACALCITOL (Curatoderm®) (NEW) | Green | Facial and Flexural psoriasis |
To prescribe most cost effective pack size for repeated use. |
Other Updates on this Website
Recent documents from LLR APC and TAS
LLRAPC Meeting Minutes August 2023(599 KB) - LMSG/LLR APC minutes
Date added: 14th Sep 2023
Continuous Glucose Monitoring- Eligibility Criteria(460 KB)
Date added: 14th Sep 2023
Residential Home Skin Tear Pathway(578 KB)
Date added: 13th Sep 2023
Patient Information Leaflet- Inhalers(886 KB)
Date added: 11th Sep 2023
Enoxaparin (Inhixa®)(107 KB) - Leicestershire drug evaluations
Date added: 7th Sep 2023
Favipiravir(200 KB) - Leicestershire drug evaluations
Date added: 7th Sep 2023
Tacalcitol(318 KB) - Leicestershire drug evaluations
Date added: 7th Sep 2023
LLRAPC Meeting Minutes July 2023(661 KB) - LMSG/LLR APC minutes
Date added: 3rd Aug 2023
About the Leicester, Leicestershire and Rutland Area Prescribing Committee
In common with other local health communities, the Leicester, Leicestershire and Rutland Area Prescribing Committee (LLR APC) acknowledges the benefits of having a Leicestershire Health Community-wide strategy for the prescribing of specialist medicines and the managed entry of new drugs and related technologies.
Leicestershire Health Community comprises the Leicester, Leicestershire and Rutland Integrated Care Board, University Hospitals of Leicester (UHL) NHS Trust and Leicestershire Partnership NHS Trust (LPT), amongst which there is a total consensus on the need for this strategy, and the LLR APC has been in place since 2005. Learn more